Pfizer Inc PFE

$30.03 -0.39 (-1.28%)

Valuation

Market cap
173,384,080,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.79
Forward PE
10.13
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
29,484,100
Avg volume
32,054,680
Day's range
$29.81 – $30.32
Shares out
5,699,674,000
Stochastic %K
82%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

focafoca99 Oct 24, 3:35 PM
$PFE revealed robust Phase 2 immune responses for its 25-valent pediatric pneumococcal vaccine candidate at IDWeek 2026. https://www.rapidticker.com/news/pfe-pfizeraposs-25-valent-pediatric-pneumococcal-3df867
0 replies
DefenseMania Oct 24, 3:35 PM
Great News !!!! $PFE https://finance.yahoo.com/healthcare/articles/pfizers-25-valent-pediatric-pneumococcal-151800354.html $MRK $AZN $LLY
0 replies
taxplanr Oct 24, 2:15 PM
$MRNA $PFE $MRK $BNTX peer reviewed Published Ivermectin Fenbendazole Menbendazole Cancer Protocol https://isom.ca/article/targeting-the-mitochondrial-stem-cell-connection-in-cancer-treatment-a-hybrid-orthomolecular-protocol/
0 replies
TopOptionAlert Oct 24, 12:21 PM
$PFE NOV20 31C · still actionable Zone: $29.82 to $30.24 Invalidation: close under $29.81 Objectives: $30.44, then $32 The math: up 1.4% to the first objective and 6.6% to the second, against 0.7% risk on the invalidation, about 9 to 1 to the second. Dear friend, picture a steady drug maker that slipped a little on Friday and still held the line it defended all day. Pfizer fell to 29 dollars and 81 cents and closed at 30 dollars and 3 cents, which tells you buyers were still there near the recent high instead of running for the door. The third quarter report lands November 3 before the open, and this November 20 call runs past that report, so you are positioned before the answer instead of chasing after it. This is a swing back toward the Thursday high, with a clear line at 29 dollars and 81 cents that says the idea is wrong if it closes under it. P.S. Watch 30 dollars and 44 cents, the Thursday high, because a close over it puts the Friday dip behind it.
0 replies
taxplanr Oct 24, 11:29 AM
The paranoid Fauci mind $MRNA $PFE $BNTX https://www.zerohedge.com/covid-19/anthony-faucis-darkest-hours
0 replies
thatsolardude365 Oct 24, 11:17 AM
$PFE: one opt-out, zero objections in Chantix. Judge Failla dismissed it with prejudice Oct 14 after final approval, with $15,000 awards for payor plaintiffs, $5,000 for consumer ones. Claims closed. Open Class Actions.
0 replies
VolumeSpreadAnalysis Oct 24, 1:03 AM
$PFE Price: $30.03 Volume: Average or below Catalyst: Investors await updates on Pfizer's oncology pipeline progress following the Seagen integration. Resistance: $31.50 Support: $28.75 Bull case: A reclaim of $31.50 on rising volume could spark a move toward the high $33S. Bear case: A breakdown below $28.75 support opens the door to a retest of 52-week lows. What I'm watching: Need to see volume expand on any move through resistance to confirm real buying interest. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio: @VolumeSpreadAnalysis
0 replies
LewisIntegrated Oct 23, 9:24 PM
$PFE gemc
0 replies